PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 207 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Survivor Guest Post: Living Breast-less June 18, 2019 ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034... June 3, 2026 Picking out the sound of tumours June 18, 2020 Shorter Course of Radiation Is Effective, Safe for Some with Early-Stage... November 30, 2022 Load more HOT NEWS Cancer in My Community: The Role of Cancer Screening in Guatemala Cancer Research UK spin-out goes public, ready to invest more in... Identical Twins Get Mirror Cancer Diagnoses Within Three Weeks Of Each... PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous...
